Compare Monster Beverage Corp (MNST) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Recursion Pharmaceuticals Inc — how do they compare? Monster Beverage Corp trades at $94.52 (market cap $93.35B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Monster Beverage Corp is far larger — about 61× Recursion Pharmaceuticals Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MNST | RXRX | |
|---|---|---|
Market Cap | $93.35B | $1.53B |
Sector | Consumer Staples | Health |
52-Week High | $99.94 | $6.79 |
52-Week Low | $58.75 | $2.84 |
Enterprise Value | $91.65B | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
